semaglutide update 2026 Update: is now an approved medication for cardiovascular diseases. It is recommended for the treatment of Type 2 diabetes and secondary prevention of cardiovascular complications in adults with established heart Compounded semaglutide for weight loss

Description

These medications slow down the stomachs emptying process

A 2024 retrospective chart review found that 67% of IBS-D (diarrhea-predominant) patients using GLP-1 medications reported moderate to significant symptom improvement within 812 weeks of starting treatment

Key Takeaway The Wegovy Savings Card is a manufacturer discount program from Novo Nordisk that can reduce your copay to as low as $25 per fill if you have commercial insurance that covers Wegovy

PMID: 128 SteinbergG

As GLP-1RAs continue to grow in popularity for managing type 2 diabetes and obesity, this pharmacovigilance study calls for increased awareness and careful perioperative planning among clinicians